The Phase 2 trial conducted by Pontificia Universidad Catolica de Chile aims to evaluate the immunogenicity superiority of booster doses with Omicron and trivalent vaccines compared to CoronaVac in adults previously vaccinated against SARS-CoV-2. Given the ongoing need for effective COVID-19 vaccines, particularly against emerging variants, the results of this trial could significantly impact market dynamics and competitive positioning for vaccine developers. The trial's completion in October 2023 positions it well for potential regulatory submissions and market entry, especially in regions with high CoronaVac usage. Collaboration with Sinovac Life Sciences Co., Ltd. may enhance commercial prospects, leveraging established distribution channels and brand recognition.